BRAF and cancer: We analyzed the TCGA papillary thyroid cancer dataset and found that RET-rearranged cancers have higher levels of ERK activity compared with BRAF/RAS mutant cancers, which may be the basis for a sensitivity to adaptive resistance after RET inhibition.